Functional antibody and T cell immunity following SARS-CoV-2 infection, including by variants of concern, in patients with cancer: the CAPTURE study.

Autor:	Fendler A; Cancer Dynamics Laboratory, The Francis Crick Institute, London, UK., Au L; Cancer Dynamics Laboratory, The Francis Crick Institute, London, UK.; Skin and Renal Units, The Royal Marsden NHS Foundation Trust, London, UK., Shepherd STC; Cancer Dynamics Laboratory, The Francis Crick Institute, London, UK.; Skin and Renal Units, The Royal Marsden NHS Foundation Trust, London, UK., Byrne F; Cancer Dynamics Laboratory, The Francis Crick Institute, London, UK., Cerrone M; Tuberculosis Laboratory, The Francis Crick Institute, London, UK.; Department of Infectious Disease, Imperial College London, London, UK., Boos LA; Skin and Renal Units, The Royal Marsden NHS Foundation Trust, London, UK., Rzeniewicz K; Cancer Dynamics Laboratory, The Francis Crick Institute, London, UK., Gordon W; Cancer Dynamics Laboratory, The Francis Crick Institute, London, UK., Shum B; Cancer Dynamics Laboratory, The Francis Crick Institute, London, UK.; Skin and Renal Units, The Royal Marsden NHS Foundation Trust, London, UK., Gerard CL; Cancer Dynamics Laboratory, The Francis Crick Institute, London, UK., Ward B; Cancer Dynamics Laboratory, The Francis Crick Institute, London, UK., Xie W; Cancer Dynamics Laboratory, The Francis Crick Institute, London, UK., Schmitt AM; Skin and Renal Units, The Royal Marsden NHS Foundation Trust, London, UK., Joharatnam-Hogan N; Skin and Renal Units, The Royal Marsden NHS Foundation Trust, London, UK., Cornish GH; Retroviral Immunology Laboratory, The Francis Crick Institute, London, UK., Pule M; Department of Haematology, University College London Cancer Institute, London, UK.; Autolus Ltd., London, UK., Mekkaoui L; Autolus Ltd., London, UK., Ng KW; Retroviral Immunology Laboratory, The Francis Crick Institute, London, UK., Carlyle E; Skin and Renal Units, The Royal Marsden NHS Foundation Trust, London, UK., Edmonds K; Skin and Renal Units, The Royal Marsden NHS Foundation Trust, London, UK., Rosario LD; Skin and Renal Units, The Royal Marsden NHS Foundation Trust, London, UK., Sarker S; Skin and Renal Units, The Royal Marsden NHS Foundation Trust, London, UK., Lingard K; Skin and Renal Units, The Royal Marsden NHS Foundation Trust, London, UK., Mangwende M; Skin and Renal Units, The Royal Marsden NHS Foundation Trust, London, UK., Holt L; Skin and Renal Units, The Royal Marsden NHS Foundation Trust, London, UK., Ahmod H; Skin and Renal Units, The Royal Marsden NHS Foundation Trust, London, UK., Stone R; Experimental Histopathology Laboratory, The Francis Crick Institute, London, UK., Gomes C; Experimental Histopathology Laboratory, The Francis Crick Institute, London, UK., Flynn HR; Mass Spectrometry Proteomics Science Technology Platform, The Francis Crick Institute, London, UK., Agua-Doce A; Flow Cytometry Scientific Technology Platform, The Francis Crick Institute, London, UK., Hobson P; Flow Cytometry Scientific Technology Platform, The Francis Crick Institute, London, UK., Caidan S; Safety, Health and Sustainability, The Francis Crick Institute, London, UK., Howell M; High Throughput Screening Laboratory, The Francis Crick Institute, London, UK., Wu M; High Throughput Screening Laboratory, The Francis Crick Institute, London, UK., Goldstone R; Advanced Sequencing Facility, The Francis Crick Institute, London, UK., Crawford M; Advanced Sequencing Facility, The Francis Crick Institute, London, UK., Cubitt L; Advanced Sequencing Facility, The Francis Crick Institute, London, UK., Patel H; Department of Bioinformatics and Biostatistics, The Francis Crick Institute, London, UK., Gavrielides M; Scientific Computing Scientific Technology Platform, The Francis Crick Institute, London, UK., Nye E; Experimental Histopathology Laboratory, The Francis Crick Institute, London, UK., Snijders AP; Mass Spectrometry Proteomics Science Technology Platform, The Francis Crick Institute, London, UK., MacRae JI; Metabolomics Scientific Technology Platform, The Francis Crick Institute, London, UK., Nicod J; Advanced Sequencing Facility, The Francis Crick Institute, London, UK., Gronthoud F; Department of Pathology, The Royal Marsden NHS Foundation Trust, London, UK., Shea RL; Department of Pathology, The Royal Marsden NHS Foundation Trust, London, UK.; Translational Cancer Biochemistry Laboratory, The Institute of Cancer Research, London, UK., Messiou C; Department of Radiology, The Royal Marsden NHS Foundation Trust, London, UK., Cunningham D; Gastrointestinal Unit, The Royal Marsden NHS Foundation Trust, London and Surrey, London, UK., Chau I; Gastrointestinal Unit, The Royal Marsden NHS Foundation Trust, London and Surrey, London, UK., Starling N; Gastrointestinal Unit, The Royal Marsden NHS Foundation Trust, London and Surrey, London, UK., Turner N; Breast Unit, The Royal Marsden NHS Foundation Trust, London, UK.; Breast Cancer Now Toby Robins Breast Cancer Research Centre, The Institute of Cancer Research, London, UK., Welsh L; Neuro-oncology Unit, The Royal Marsden NHS Foundation Trust, London, UK., van As N; Clinical Oncology Unit, The Royal Marsden NHS Foundation Trust, London, UK., Jones RL; Sarcoma Unit, The Royal Marsden NHS Foundation Trust and Institute of Cancer Research, London, UK., Droney J; Palliative Medicine, The Royal Marsden NHS Foundation Trust, London, UK., Banerjee S; Gynaecology Unit, The Royal Marsden NHS Foundation Trust, London, UK., Tatham KC; Anaesthetics, Perioperative Medicine and Pain Department, The Royal Marsden NHS Foundation Trust, London, UK.; Department of Surgery and Cancer, Imperial College London, London, UK., Jhanji S; Anaesthetics, Perioperative Medicine and Pain Department, The Royal Marsden NHS Foundation Trust, London, UK., O'Brien M; Lung Unit, The Royal Marsden NHS Foundation Trust, London, UK., Curtis O; Lung Unit, The Royal Marsden NHS Foundation Trust, London, UK., Harrington K; Head and Neck Unit, The Royal Marsden NHS Foundation Trust, London, UK.; Targeted Therapy Team, The Institute of Cancer Research, London, UK., Bhide S; Head and Neck Unit, The Royal Marsden NHS Foundation Trust, London, UK.; Targeted Therapy Team, The Institute of Cancer Research, London, UK., Bazin J; Haemato-oncology Unit, The Royal Marsden NHS Foundation Trust, London, UK., Robinson A; Haemato-oncology Unit, The Royal Marsden NHS Foundation Trust, London, UK., Stephenson C; Haemato-oncology Unit, The Royal Marsden NHS Foundation Trust, London, UK., Slattery T; Skin and Renal Units, The Royal Marsden NHS Foundation Trust, London, UK., Khan Y; Skin and Renal Units, The Royal Marsden NHS Foundation Trust, London, UK., Tippu Z; Skin and Renal Units, The Royal Marsden NHS Foundation Trust, London, UK., Leslie I; Skin and Renal Units, The Royal Marsden NHS Foundation Trust, London, UK., Gennatas S; Acute Oncology Service, The Royal Marsden NHS Foundation Trust, London, UK.; Department of Medical Oncology, Guy's Hospital, London, UK., Okines A; Breast Unit, The Royal Marsden NHS Foundation Trust, London, UK.; Acute Oncology Service, The Royal Marsden NHS Foundation Trust, London, UK., Reid A; Uro-oncology Unit, The Royal Marsden NHS Foundation Trust, Surrey, UK., Young K; Skin and Renal Units, The Royal Marsden NHS Foundation Trust, London, UK., Furness AJS; Skin and Renal Units, The Royal Marsden NHS Foundation Trust, London, UK., Pickering L; Skin and Renal Units, The Royal Marsden NHS Foundation Trust, London, UK., Gandhi S; Neurodegeneration Biology Laboratory, The Francis Crick Institute, London, UK.; UCL Queen Square Institute of Neurology, London, UK., Gamblin S; Structural Biology of Disease Processes Laboratory, The Francis Crick Institute, London, UK., Swanton C; Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK.; University College London Cancer Institute, London, UK., Nicholson E; Haemato-oncology Unit, The Royal Marsden NHS Foundation Trust, London, UK., Kumar S; Gastrointestinal Unit, The Royal Marsden NHS Foundation Trust, London and Surrey, London, UK., Yousaf N; Lung Unit, The Royal Marsden NHS Foundation Trust, London, UK.; Acute Oncology Service, The Royal Marsden NHS Foundation Trust, London, UK., Wilkinson KA; Tuberculosis Laboratory, The Francis Crick Institute, London, UK.; Wellcome Center for Infectious Disease Research in Africa, University Cape Town, Cape Town, Republic of South Africa., Swerdlow A; Division of Genetics and Epidemiology and Division of Breast Cancer Research, The Institute of Cancer Research, London, UK., Harvey R; Worldwide Influenza Centre, The Francis Crick Institute, London, UK., Kassiotis G; Retroviral Immunology Laboratory, The Francis Crick Institute, London, UK., Larkin J; Skin and Renal Units, The Royal Marsden NHS Foundation Trust, London, UK., Wilkinson RJ; Tuberculosis Laboratory, The Francis Crick Institute, London, UK.; Department of Infectious Disease, Imperial College London, London, UK.; Wellcome Center for Infectious Disease Research in Africa, University Cape Town, Cape Town, Republic of South Africa., Turajlic S; Cancer Dynamics Laboratory, The Francis Crick Institute, London, UK. samra.turajlic@crick.ac.uk.; Skin and Renal Units, The Royal Marsden NHS Foundation Trust, London, UK. samra.turajlic@crick.ac.uk.
Jazyk:	angličtina
Zdroj:	Nature cancer [Nat Cancer] 2021 Dec; Vol. 2 (12), pp. 1321-1337. Date of Electronic Publication: 2021 Oct 27.
DOI:	10.1038/s43018-021-00275-9
Abstrakt:	Patients with cancer have higher COVID-19 morbidity and mortality. Here we present the prospective CAPTURE study, integrating longitudinal immune profiling with clinical annotation. Of 357 patients with cancer, 118 were SARS-CoV-2 positive, 94 were symptomatic and 2 died of COVID-19. In this cohort, 83% patients had S1-reactive antibodies and 82% had neutralizing antibodies against wild type SARS-CoV-2, whereas neutralizing antibody titers against the Alpha, Beta and Delta variants were substantially reduced. S1-reactive antibody levels decreased in 13% of patients, whereas neutralizing antibody titers remained stable for up to 329 days. Patients also had detectable SARS-CoV-2-specific T cells and CD4 + responses correlating with S1-reactive antibody levels, although patients with hematological malignancies had impaired immune responses that were disease and treatment specific, but presented compensatory cellular responses, further supported by clinical recovery in all but one patient. Overall, these findings advance the understanding of the nature and duration of the immune response to SARS-CoV-2 in patients with cancer. (© 2021. The Author(s).)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu Full text from SpringerLink